Growth Hormone for the Treatment of Gastroparesis

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Mayo Clinic
Study ID
NCT06803589
Phase
EARLY_PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Gastroparesis

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Growth Hormone — DRUG
    Subjects will receive somapacitan-beco (Sogroya®) administered as a subcutaneous injection once weekly for 12 weeks. All participants will receive a fixed dose of 1.5 mg weekly, regardless of sex.

Study Details

The purpose of this study is to determine whether treatment with Growth Hormone results in symptomatic improvement in patients with gastroparesis.

Key Dates

Start date
Oct 22, 2024
Status verified
Apr 2026
Primary completion
Oct 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment Group
    Patients with Gastroparesis

Primary Outcome Measure

Gastroparesis Cardinal Symptom Index (GCSI) [ Time Frame: Baseline, 4 weeks, 8 weeks, 12 weeks, 14 weeks ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Mayo ClinicPhoenixArizona85054
Guillermo Barahona Hernandez, Sr. Progam Coordiantor
480-301-4679
Mayo Clinic in ArizonaScottsdaleArizona85259
Guillermo Barahona Hernandez, Program Coordinator, Research, 480-301-4679
[email protected]
Tisha Lunsford, MD
[email protected]
480-301-6990
Tisha Najet Lunsford (PRINCIPAL_INVESTIGATOR)

Find similar trials in Phoenix, AZ

By research site
Mayo Clinic· Phoenix, AZMayo Clinic in Arizona· Scottsdale, AZ

Related Studies